Study objective-The aim was to estimate costs and yields of faecal occult blood screening and rescreening for colorectal cancer, for differing age cohorts.
Participants-Approximately 140 000 subjects, age 50-79 years, were randomly allocated to a test (screened) and a control (unscreened) group.
Main results-The net costs of detecting and treating a cancer following colorectal screening fall as the age of the target population increases, owing principally to the increasing incidence of the disease with age. Generally, the marginal detection and treatment cost falls for all age groups with the first screening round, but rises considerably with the second. If allowance is made for cancers prevented as a result of early detection and excision of adenomas, the costs of screening are substantially reduced for all age groups.
Conclusions-Assuming a cost per QALY (quality adjusted life year gained) equivalent to that derived for the breast cancer screening programme, and a QALY gain from colorectal screening of one year, three screens, each separated by two years, appear economically justified for populations aged 60 years and above. Expected gains from cancer prevention make two screens justifiable for those between 45 75 years. This range is determined by considerations of incidence (lower age limit) and the ability to undergo treatment (upper limit).
To date, the economic evaluation of colorectal screening in terms of subject age has been neglected-the only published report indicates that beginning screening at age 40 rather than 50 years of age would be likely to produce little benefit but would double the cost of a lifetime screening programme.5 However, age effects have been considered in other screening applications, and with significant findings. Opportunistic cholesterol testing, for example, has been costed at £200 per quality adjusted life year gained (QALY) for men, aged 40 to 69 (with diet therapy), but at £14 150 per QALY for men aged 25 to 39.6 An evaluation of breast cancer screening for women aged 40-49 years has also been conducted, predicting increases in life expectancy for those screened but at very considerable cost. 7 The present paper is based on data from the colorectal screening trial presently under way in Nottingham, England.8 To date, this trial has recruited approximately 140 000 subjects in its control and study groups, making it by far the largest randomised controlled colorectal screening trial currently in operation. The aims of this paper are, first, to provide an order of magnitude estimate of the costs of detecting and treating a cancer by colorectal screening for different age ranges and, second, to assess the benefits which would have to result to make the implementation of colorectal screening economically justifiable.
Methods
Were mass screening for colorectal cancer for the 45-75 year age range to be introduced into the United Kingdom, it would involve the recruitment of approximately 17 million subjects. We shall assume that the screening protocol would be broadly similar to that employed in the Nottingham trial, and that the results of this trial may be generalised to the population at large.
Thus, screening targets would be issued with a HaemoCCultTM faecal occult blood test which they would be asked to complete by depositing stool samples collected over a number of days on guaiac impregnated paper. Samples would be returned to the test centres for development. The addition of a reagent produces a characteristic colour change in the presence of occult blood in the stool, itself an indicator of bowel abnormality. Subjects with positive test results would receive a confirmatory diagnostic investigation, principally colonoscopy. Initially, the Nottingham trial experimented with both three day and six day occult blood testing, although, for reasons which will become clear shortly, it now employs only three day tests. Compliant subjects would be offered three day faecal occult blood retesting every two years, as has occurred throughout the trial.
Viable trial data currently exist for three screening rounds. These comprise data relating to (1) subject compliance-the proportion of tests issued which are completed and returned for development; (2) positive rate-the proportion of completed tests which prove positive on development; (3) the cancer yield, from which may be derived the detection rate (yield per test completed). These data form parameters for a model previously developed,9 from which the average variable costs of cancer detection by screening in a population of asymptomatic individuals may be estimated. This model employs 1989-1990 costs of labour, capital, and disposables employed in faecal occult blood testing and follow up investigation, based on an "average" Family Health Service Authority (FHSA) area of 75 000 target individuals. The FHSAs, we assume, would form the basic building blocks of a national screening programme.
As originally constructed, the model generated gross costs of cancer detection by screening, to which must be added, for present purposes, the expected costs of cancer treatment. We have used a treatment cost equivalent to 17 days of inpatient stay, an estimate determined by an earlier Nottingham study. ' 1 Of particular relevance in the present context, however, are net costs. The alternative to detection by screening is detection by symptomatic presentation, which would require both a confirmatory diagnostic investigation and a course of treatment similar to that employed under the screening protocol, albeit at some point in the future. As the time interval between the development of a cancer and its symptomatic presentation is not known with certainty, we have estimated these latter costs assuming both a two year and a five year presentation lag, ie, the costs of future symptomatic presentation and treatment have been discounted over these time intervals. The net cost of detection and treatment by screening is accordingly the difference between (1) gross detection and treatment costs incurred in the present, and (2) discounted future investigation and treatment costs.
Faecal occult blood screening is capable of detecting two forms of neoplasia, adenomas, which are benign tumours, and carcinomas, which are malignant. The significance of this property of the test lies in the accepted belief that a high proportion of colorectal cancers arise in adenomas, and that an adenoma therefore possesses some finite probability of becoming malignant over time." During investigative colonoscopy, adenomas may be excised as part of the procedure, at minimal additional cost. The routine excision of adenomas detected during screening therefore implies that screening has an inportant role in cancer prevention.
A model has been developed of adenoma malignancy probabilities over time'2 13 using published data on the long term follow up of adenomas in excess of 1 cm in diameter.'4 Thus, for example, it has been shown that an adenoma patient with a 20 year life expectancy has a 2500 chance of developing a malignancy in that adenoma. Using trial data on adenoma yield by five year age cohort, it is thus possible to model the number of cancers likely to develop within the expected lifetimes of the patients. Yield can therefore be reinterpreted as cancers both detected and prevented and costs calculated in a manner equivalent to that for detection alone. The prevention variant also makes an additional allowance for cost savings on all future investigations and treatments which would have been required, had the adenomas been allowed to develop and present as cancers.
Results
The trial data relevant to our cost estimates appear in table I. They were originally collected for five year age cohorts and then pooled into the three age ranges, because the very low prevalence of neoplasia gives rise to yields in five year cohorts too small to demonstrate statistical significance. The data show that compliance increases with each screening round and that it peaks in the middle of the target population age range. Both positive tests and detection rates increase with age, but decrease as the number of rescreens increases. These findings are broadly in agreement with those of the Danish trial15 16 which has a similar protocol to that employed in Nottingham. With respect to the initial three day screen, differences in the number of cancers detected in the three age ranges are statistically significant (X2 at 500). More cancers, in other words, are detected in older age ranges, as would be expected from the symptomatic incidence data presented earlier. For six day testing, the > 70 years yield is significantly different from the other two age ranges. The difference between the 45-59 age range and the other two is significant (at 0-500) in the first rescreen. Relatively fewer additional cancers are accordingly detected by rescreening the younger age group. The inclusion of prevented cancers does not affect the significance of the differences between yields except in one respect-the yield difference for the first two age groups on the initial screen now becomes insignificant.
Finally, it should be noted that both cancer and adenoma yields from six day and three day faecal occult blood testing on the initial screen are not significantly different from one another, reinforcing the conclusions of an earlier study. 7 Moreover, the costing model has previously shown that six day screening costs are 24%0, higher than those of three day screening.9 Accordingly, the six day screening option will not be considered further. round. The sharp increase in cost beyond the first rescreen is grounds for believing that the time interval for this later round might profitably be extended to increase yield.
In terms of identifying the most efficient age group to screen, the effects of cancer prevention by adenoma excision are extremely important. Ignoring this effect would mean that it would be considerably harder to justify screening those younger than 60 years ofage on economic grounds, especially beyond the first rescreen. In particular, no cancers have been detected in those aged under 50 years in either the Nottingham or the Danish trial, and a Swedish trial report has advocated 55 years as a lower age limit in view oflow incidence at younger ages.26 Given the longer life expectancy of the younger group, however, there is a correspondingly higher probability that excised adenomas of 1 cm or more in diameter would have become malignant within their lifetimes. The importance of this effect naturally lessens as the age at which the adenoma is excised increases.
In 
